Investigational drug study for high and very high risk myelodysplastic syndromes

Trial ID:
IRB-17-7017
Marin Xavier, MD
This study will evaluate the safety and effectiveness of investigational drug, Pracinostat, in combination with Azacitidine in patients with high to very high risk Myelodysplastic Syndrome (MDS) who cannot tolerate or do not qualify for routine treatment with commercially available agents.

Inclusion Criteria

  • Be 18 years of age or older
  • Be diagnosed with Myelodysplastic Syndrome (MDS) and have not been previously treated with hypomethylating agents (HMAs)
  • Be willing and able to undergo bone marrow aspiration and biopsy at the start of and during the study.

Exclusion Criteria

  • Have had other cancers within 12 months (certain breast, cervical, skin or prostate are allowed)
  • Have had prior treatment for MDS with histone deacetylase (HDAC) inhibitors or other investigational agents
  • Be pregnant or planning to become pregnant

Additional Info

  • Pracinostat inhibits specific proteins that may stop or reverse the growth of cancerous cells. Azacitidine is approved by the FDA for the treatment of MDS. Both drugs will be given together.
  • All treatments and physician visits during this study will take place at Scripps Clinic Torrey Pines or Scripps Mercy Cancer Center.

Contact Info: